Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
The accelerated approvals of Kymriah (Novartis) for the treatment of children oryoung adults with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and Yescarta (Kite Pharma, a Gilead company) for relapsed/refractory large B-cell lymphoma herald a new era in cancer immunotherapy. In this report, we present a comprehensive market forecast for the current and emerging chimeric antigen receptor (CAR) T-cell therapies across oncology indications. We also provide key opinion leaders’(KOLs’) insights regarding the current and emerging CAR T-cell treatment landscape.
United States, EU5, Japan
14 country-specific interviews with thought-leading hematologist-oncologists and trial investigators.
Drug-treated patient populations for acute lymphoblastic leukemia, relevant non-Hodgkin’s lymphoma subpopulations, chronic lymphocytic leukemia, and multiple myeloma, by country and line of therapy.
Ten-year, annualized, drug-level sales and patient shares for CAR T-cell therapies through 2027, segmented by indication and patient subpopulation.
The CAR T-Cell Therapy Special Topics Report is a unique product offering a consolidated full market forecast of the CAR T-cell landscape in oncology through 2027. This forecast is supplemented with interviews conducted with KOLs from all seven major pharmaceutical markets under study.
Already a Client? Log in to access this report.
Andrew Merron, is the Therapy Lead for oncology and biosimilars at Decision Resources. In this capacity he is responsible for the team delivering high quality, timely, and relevant insights and forecasts. In addition, Dr. Merron drives the strategic direction of the team, builds and maintains long-term strategic partnerships with clients, and translates domain knowledge into substantial value for the department. Previously, Dr. Merron managed the Biosimilars Advisory Service across therapy areas, and prior to this he was a principal analyst in the oncology group. He has extensive experience in forecasting oncology and hematology-oncology drug markets as well as considerable experience in conducting primary research with physicians and payers. Prior to joining Decision Resources, Dr. Merron received his in molecular oncology from the University of London. His doctorate focused on molecular imaging of cancer immunotherapies, specifically therapeutic oncolytic adenoviruses.